Xolair - Biological Therapy for the Treatment of Asthma
Key Data:
Drug (brand/generic)
Xolair (omalizumab)
Company/licensee
Tanox, Genentech, and Novartis,
Therapy class
Therapeutic MAb
Product description
Recombinant humanised anti-IgE MAb
Current indication
Allergic asthma in adults and adolescents
Market sector
Respiratory
Development status
Approved US June 2003, pre-registration Europe
